PRESERVE-003: Phase 3, two-stage, randomized study of ONC-392 versus docetaxel in metastatic non-small cell lung cancers that progressed on PD-1/PD-L1 inhibitors. Meeting Abstract

cited authors

  • Socinski, Mark A.; He, Kai; Li, Tianhong; Chen, Dan; He, Kun; Liu, Yang; Zheng, Pan

Publication Date

  • June 1, 2023

webpage

published in

category

volume

  • 41

issue

  • 16